Tenatoprazole Explained

Tenatoprazole is a proton pump inhibitor drug candidate that was undergoing clinical testing as a potential treatment for reflux oesophagitis and peptic ulcer as far back as 2003.[1] The compound was invented by Mitsubishi Tanabe Pharma and was licensed to Negma Laboratories (part of Wockhardt as of 2007[2]).

Mitsubishi reported that tenatoprazole was still in Phase I clinical trials in 2007[3] and again in 2012.[4]

Tenatoprazole has an imidazopyridine ring in place of the benzimidazole moiety found in other proton pump inhibitors, and has a half-life about seven times longer than other PPIs.[5]

See also

Notes and References

  1. Web site: DataMonitor . March 2003 . Gastrointestinal Disease Update . Digestive Disease Week.
  2. Web site: Economic Times . 3 March 2011 . Investors unwilling to forgive Wockhardt, promoter for failings .
  3. Web site: Mitsubishi Tanabe Pharma . FY2007 Interim Financial Results .
  4. Web site: Mitsubishi Tanabe Pharma . State of New Product Development . 8 May 2012 .
  5. Li H, Meng L, Liu F, Wei JF, Wang YQ . H+/K+-ATPase inhibitors: a patent review . Expert Opinion on Therapeutic Patents . 23 . 1 . 99–111 . January 2013 . 23205582 . 10.1517/13543776.2013.741121 . 44647770 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Tenatoprazole".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.